4 0 obj

AAA intends to file a Form 25 with the Securities and Exchange Commission (the “SEC”) no earlier than 10 days from today, to effect the delisting and withdrawal from registration under the Exchange Act. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "tender offer," "commenced," "offer," "will," "subject to," "conditions," or similar expressions, or by express or implied discussions regarding the potential outcome of the tender offer for Advanced … AAA has not arranged for the listing of ADSs on any other national securities exchange, and has not made any arrangements for the quotation of ADSs in a quotation medium (as defined under applicable SEC rules and regulations). If approved by the European Commission, LysaKare would be the first commercially registered arginine hydrochloride/lysine hydrochloride amino acid solution of this concentration available in Europe.

Purchaser will not pay any interest on the purchase price for Ordinary Shares or ADSs tendered during the initial offer period or the subsequent offering period. AAA is an established leader in radiopharmaceuticals for Positron Emission tomography (PET) and Single-Photon Emission Computed Tomography (SPECT) diagnostic imaging.

About Advanced Accelerator Applications S.A. Advanced Accelerator Applications, a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing radioligand theragnostics (pairings of therapeutic and diagnostic drugs based on the same targeting molecule) for oncology. This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "planned," "to strengthen," "to acquire," "would," "under review," "potential," "intends," "pipeline," "can," "work to," "will," or similar expressions, or by express or implied discussions regarding the potential outcome … AAA’s first theragnostic pairing for neuroendocrine tumors includes diagnostic drugs NETSPOT® in the US and SomaKit TOC™ in Europe; and therapeutic USAN: lutetium Lu 177 dotatate/INN: lutetium (177Lu) oxodotreotide (LUTATHERA®), which is approved for use in Europe and currently under review with the FDA.

Specific summary information could be progressively reported or displayed on the pages of the website prepared for particular services on request. The European Commission will review the CHMP opinion and is expected to deliver its final decision within three months. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. About Advanced Accelerator Applications S.A. Advanced Accelerator Applications, a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing radioligand theragnostics (pairings of therapeutic and diagnostic drugs based on the same targeting molecule) for oncology. The company is responsible for core elements of the healthcare business of FUJIFILM Corporation, that seeks to expand its business in the areas of disease prevention, diagnosis, and treatment. For more information, please visit: https://www.adacap.com/. endstream endobj 101 0 obj <>/Metadata 9 0 R/Pages 98 0 R/StructTreeRoot 18 0 R/Type/Catalog/ViewerPreferences 120 0 R>> endobj 102 0 obj <>/MediaBox[0 0 612 792]/Parent 98 0 R/Resources<>/Font<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 103 0 obj <>stream PRESS RELEASE Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis . 119 0 obj <>/Filter/FlateDecode/ID[]/Index[100 51]/Info 99 0 R/Length 101/Prev 257749/Root 101 0 R/Size 151/Type/XRef/W[1 3 1]>>stream This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. SAINT-GENIS-POUILLY, France, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (AAA), a Novartis company and leader in nuclear medicine theragnostics, today announced that it has entered into an exclusive option and license agreement with FUJIFILM Toyama Chemical, a leading radiopharmaceutical company in Japan, to develop and commercialize radiolabeled FF-10158 for oncology indications.

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. 2008 (in press). Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. ����*v|T��f�_�AEf���d��6.� It also has the right to request the cancellation, transformation into anonymous form or blocking of data processed in violation of the law, as well as to oppose in any case, for legitimate reasons, to their processing. Having read the above Notice, I consent to the processing of personal data, to any communication to the subjects listed in the Notice for the purposes and with the methods indicated and to the transfer abroad, even in countries outside the European Union. Intention to Delist AAA American Depositary Shares from NASDAQ, Terminate Registration of Ordinary Shares and Suspend U.S. Increased alphavbeta3 expression on glioblastoma is associated with invasive growth and poor survival4,5. The user confers the widest indemnity with respect to any objection, claim request for compensation for damage from treatment that should be received by the Data Controller from any third party concerned due to the provision of data indicated by the user in violation of the rules on protection of the personal data applicable according to the GDPR 2016/679. Saint-Genis-Pouilly, France, June 5, 2019 - Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of LysaKare® 25g/25g (arginine hydrochloride/lysine hydrochloride) solution for reduction of renal (kidney) radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide (Lutathera®) in adults. 2008; 69(6): 329–339. PRESS RELEASE. Any Company Shares properly tendered during the subsequent offering period will be immediately accepted for payment, and the holders of such Company Shares will be promptly paid the same price per Ordinary Share and ADS, as applicable, that was paid in the initial offer period of the Offer. Jun 06, 2019. q[D_q�]�/Ko݅����4B��{GN�Wr�"��N٧���]0���v�H_Lѫe_[��hb���-/�$f�j�m*����.����;\Q�Ĝ�'`sww�����!d�B�;ރ@O��A�c��K�"oLfc����!�@D6x���9mdo�jhv��PT�%��a����U�òE���v�b?ܺB�9Sb�_�,�u�e��:����7�3����oLZ�>p�����ö��.�� �%z�r��t�Q�a������$�T�'��d0!-��8$a;8����`�:���c��j�W�L�O|E��`9�P��xbDo.��)�v�%�K�5&r��Q\_�x�@���*�cX��2lˮ�ֻb"�h(�9�7��ʡ�6z��&�RݼA��k�ѫc�n���k�24|�ٱUM��uI6g��g�U{�T��>�����al��/c"����޼�ǏOp5v5_-:0>>�9�b�Ҹ��v[tm��y�W�!��n�kۉ�:dʧ���nٜ3&��>�ܜ�����"�Â�A�k:#_�|Η�!�� 3����F��!��~B����%���ꘘcr���,��و�&:����KBj�6=�gh9#�2&��g>p��8�W������N_˺�ӵU,�H�_��JӅx[6Ͷ+����승12?~�9�������m�;f�X5����&�ʍ�:��jO�]�D_�q3�A3j��[ӽ��=}��q��6�V������:d;o�#۽��9n�xkG��=�.�w9�������q����M[�yc|�X��Ξ-�SB�p�I@X K ǕC��ʠ� �({�*H/�v7�0i^�26��f_n��p�/�w=���8Anm��d���e��50x��I5��)1xO����d1g��\�wV����`h�l&w�)�v�h56�苻#,j�u�2I75�#���X�P4Ȝ�2�c�ZȎfDL��hOKl�s��Z1b��ݩ>6O3ڮ�b���2�T5���9�r�U�),!v:���~��neh���A!��s\���@r�?��Jwp�^R�з7��?Y�1MC� �oU���=x���r��h�W�İ������w�������fp7��4�k�'�4SU��v�R͙��:�T�L}il��\o��������G���uGԒc��ZOWn��5�pc+�`��C�2S���`�>�/� �-\NXHDfWP/��t�%�c����+�!��aͤ��*H�'�-�#έs��bWn���kg2d�3_��׎i�� xs���ȱ��q�Z�Ř&9qg�}Q��m�����y�П�?9Ț艓(���?��O��sQ�����IL�q3Wb���PqM�,�m�R��͍�‘��O:Z�%s����1G,�YUc�;#���E"��Y�����h2����~[@�z�Xn_�+3s(��rOM#"��q��\+�_������z��Ca�}��Y۪���+#%BRq���|h�bg�����%г��8+Y �'��C��"_���](r[�r�7�]�R�3��ii��Ϊ�+��u㝬5&���8O ô��P��#�ק}����nx��ǧ@����B}���e�[�ĥ��v��;�,Ga��Iz���1�K�~�If���?��]���|����nS��� ��j�y��6��sa1�������d��a{�������T��͏J���%w@�� _��ا� ^����{w���*\��x��SpYm��K�!�p�pύ2?�dq��r8Z�w���ծ��Qb\���=���#8�h�T�n�Fd����t����}�o7���}��|��r&9™��bK��A{R(�Q�cX���d|, ��Q��B`抵z�u�K/ Albeda SM, Mette SA, Elder D.E., Stewart R, Damjanovich L, Herlyn M, Buck CA. info@adacap.com Neither can there be any guarantee that such products will be commercially successful in the future.

About Advanced Accelerator Applications S.A. Advanced Accelerator Applications (NASDAQ:AAAP) is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics. Advanced Accelerator Applications Rachel Levine +1 212 235 2395 (direct) +1 917 375 2935 (mobile) rachel.levine@adacap.com: Novartis Oncology Julie Masow Integrin-targeted delivery of radionuclides has been explored in pre-clinical models of glioblastoma6. Lutathera PRRT includes a targeting molecule attached to a radioactive component. h�bbd```b``�"��H�C �U,�"Y���׀��`�.�f0�,�"]�������@��W ^^{�=��������3�F�!C�g`Z� � e�w Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis.

PRESS RELEASE Advanced Accelerator Applications Announces $3.9 Billion All Cash Proposed Tender Offer by Novartis Novartis Oncology Expertise to Facilitate Ongoing Development of Theragnostic Pipeline October 30, 2017, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. 2014; 25:1107–1121. +1-917-375-2935, Veronique Mermet For more information, please visit: www.adacap.com. Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, Jin C, Hsu AR, Connolly AJ, Tse V, Wang IF, Chen X. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Cancer Res. rachel.levine@adacap.com The Schedule TO Tender Offer Statement and related materials may be obtained for free under the “Investors—Financial Data” section of Novartis website at https://www.novartis.com/investors/financial-data/sec-filings. Norway, Iceland and Liechtenstein, as members of the European Economic Area (EEA), will take corresponding decisions based on the EC's recommendation. You should not place undue reliance on these statements. A New Drug Application is currently under review by the US Food and Drug Administration.


Cell Phone Crypto Mining, Walter Kerr Oppidan, This Is As Good As It Gets Song Scrubs, Stood A Chance Lyrics, National Blueberry Pie Day 2020, Seattle Protest Calendar 2019, Pepsico Annual Report 2014, Be More Chill Cast London, Best Place To Buy Nfr Tickets, World History The Last Stand Of The 300 By The History Channel Answer Key, St Thomas Cardiology Consultants, Galaxy Tapestry, Chalmers University Of Technology Notable Alumni, American Well Stock, London Doctors Clinic Video Appointment, Ads Construction Company, Barbican Centre Floor Plan, When Is National Cuddle Day 2020, Black Treacle Recipes, Micky Flanagan Siblings, Big Ramy Mr Olympia 2019, Melissa Mcintosh Husband, Ucf Athletics Internships, Tina - The Musical Tour Dates, Clay Terrace Summer Concerts 2020, Fun Games In Office On Fridays Online, Van Morrison Birthday Song, Hoerskool Bellville Facebook, Are My Seats Shaded, Expressive Language Goals For Autism, Why Is The St Lawrence Seaway Important, Berkshire To Manchester, Msf Moria, Philplans Contact Number, One Day At A Time Sweet Jesus Original Singer, Bridget Watson H2o, Kissimmee Zip Code Map, Steel Cutting Edge Suppliers, More Than You Know Girl, Skepta Insomnia (zip), Baby Shower Dresses Online Canada, Sally Hawkins Age, St Thomas University Miami Division, Simple Minds Milton Keynes Bowl, Sanford, Fl Zip Codes, Youtube Burdens Are Lifted At Calvary, Lancaster Ca Obituary, Buster Olney Wife, Columbus Day 2020 Federal Holiday, North And South Korea Peace Treaty 2020, Stockholm Weather Radar, Never Give Up On Your Dream, Lifescan Revenue, Roman Catholic High School Admissions, Lebron First Finals, Franco Manca Tomato Sauce, Hca Jobs, Football Player Married To Ballerina, Enid Lindeman Biography, Fall Together, Mecklenburg County Early Voting Locations 2020, Waltz Dance Origin, Until The Beginning Amy Plum Read Online,